Format

Send to

Choose Destination
J Pediatr Rehabil Med. 2019 Jun 10. doi: 10.3233/PRM-180552. [Epub ahead of print]

Safety of combined salivary gland and multilevel intramuscular onabotulinumtoxinA injections with and without ethanol in pediatric patients with cerebral palsy: A retrospective study.

Shoval H1, Levin J2,3, Friel K4,5,6, Kim H2,3.

Author information

1
Pediatric Physical Medicine and Rehabilitation, Children's Specialized Hospital, Clifton, NJ, USA.
2
Pediatric Physical Medicine and Rehabilitation, Columbia University Medical Center and Weill Cornell Medical College New York Presbyterian Hospital, New York, NY, USA.
3
Physiatry, Blythedale Children's Hospital, Valhalla, NY, USA.
4
Burke Neurological Institute, White Plains, NY, USA.
5
Brain-Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
6
Blythedale Children's Hospital, Valhalla, NY, USA.

Abstract

OBJECTIVE:

To evaluate the safety of combining salivary gland onabotulinumtoxinA (BTX-A) injections for sialorrhea with intramuscular BTX-A injections for spasticity in the same procedure.

DESIGN:

A retrospective cohort study in a tertiary hospital center. Patients selected were younger than 20 years, diagnosed with cerebral palsy, and received their first salivary gland BTX-A injection between March 2011 and July 2015. Chart reviews and telephone interviews were performed. The primary outcome measure was the rate of adverse events after combined BTX-A injections into salivary glands and muscles. The secondary outcome measure was the efficacy of injections, as reported by patients.

RESULTS:

Twenty-five of the 52 selected patients received salivary gland BTX-A injections only, and 27 received concurrent salivary gland and multi-level intramuscular chemodenervation with BTX-A injections. The rate of adverse events was < 10% in both groups: 4% in "salivary only" group and 7% in the group with salivary + multi-level intramuscular chemodenervation with BTX-A (with or without alcohol). Both approaches were equally effective in meeting their goals of salivary injections (> 50% improvement for at least two months). In the "salivary only" and in the "salivary + multi-level intramuscular" group, 76 and 85% of the patients reached their goals respectively.

CONCLUSIONS:

Combining BTX-A injections for sialorrhea with multilevel intramuscular BTX-A injections (with or without alcohol) appears to be safe and effective and allows treatment of patients for both conditions simultaneously.

KEYWORDS:

OnabotulinumtoxinA injection; cerebral palsy; diffuse spasticity; sialorrhea

PMID:
31227667
DOI:
10.3233/PRM-180552

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center